FDA Update on Autism Drug: Clinical Perspective from Dr. David Danish
In a recent article by The Epoch Times, federal regulators announced the withdrawal of approval for a branded form of leucovorin (Wellcovorin), clarifying that the decision was administrative and does not impact the availability of generic leucovorin or its current medical use. The piece also highlights prior federal statements expressing interest in leucovorin as a potential treatment for autism, alongside ongoing uncertainty in the broader evidence base.
Dr. David Danish provides clinical context, explaining how leucovorin may help certain individuals with autism by bypassing folate transport issues in the brain. He emphasizes that this regulatory update should not distract from the meaningful, evidence-based improvements observed in appropriately selected patients, while acknowledging that further research is still needed.
Interested in how this evolving landscape translates to real-world care, and which patients may actually benefit?
Read on for a closer look at the science and clinical considerations.
Back to Blog
Disclaimer: This guide is for informational purposes only and not a substitute for medical advice. Any treatment—whether a supplement, medication, procedure, injection, therapy, or device—carries potential risks, especially when used in excess or by individuals with certain medical conditions or genetic predispositions. Always consult a qualified healthcare provider before starting any treatment.